GVAX Pancreas (allogeneic GM-CSF-secreting tumor cells) / Novartis 
Welcome,         Profile    Billing    Logout  
 9 Diseases   5 Trials   5 Trials   302 News 


123»
  • ||||||||||  GVAX Pancreas (allogeneic GM-CSF-secreting tumor cells) / Novartis, Opdivo (nivolumab) / Ono Pharma, BMS
    Trial completion, Trial completion date, Trial primary completion date, Combination therapy:  GVAX Pancreas Vaccine (With CY) in Combination With Nivolumab and SBRT for Patients With Borderline Resectable Pancreatic Cancer (clinicaltrials.gov) -  Feb 29, 2024   
    P2,  N=28, Completed, 
    Altogether our findings shed light on the plasticity of TLS in neoadjuvant immunotherapy and suggest future immunotherapy approaches should target both humoral and cytotoxic NK/T cell compartments to augment responses in solid tumors. Active, not recruiting --> Completed | Trial completion date: Sep 2024 --> Feb 2024 | Trial primary completion date: Sep 2024 --> Feb 2024
  • ||||||||||  BMS-813160 / BMS, GVAX Pancreas (allogeneic GM-CSF-secreting tumor cells) / Novartis, Opdivo (nivolumab) / Ono Pharma, BMS
    Trial completion date, Trial primary completion date, Metastases:  Trial of Neoadjuvant and Adjuvant Nivolumab and BMS-813160 With or Without GVAX for Locally Advanced Pancreatic Ductal Adenocarcinomas. (clinicaltrials.gov) -  Feb 15, 2024   
    P1/2,  N=30, Recruiting, 
    Active, not recruiting --> Completed | Trial completion date: Sep 2024 --> Feb 2024 | Trial primary completion date: Sep 2024 --> Feb 2024 Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024
  • ||||||||||  GVAX Pancreas (allogeneic GM-CSF-secreting tumor cells) / Novartis, Opdivo (nivolumab) / Ono Pharma, BMS
    Trial completion date, Trial primary completion date, Combination therapy:  GVAX Pancreas Vaccine (With CY) in Combination With Nivolumab and SBRT for Patients With Borderline Resectable Pancreatic Cancer (clinicaltrials.gov) -  Jul 28, 2023   
    P2,  N=30, Active, not recruiting, 
    Trial completion date: Sep 2023 --> Sep 2024 | Trial primary completion date: Sep 2023 --> Sep 2024 Trial completion date: Jun 2023 --> Sep 2023 | Trial primary completion date: Jun 2023 --> Sep 2023
  • ||||||||||  Trial completion date, Trial primary completion date, IO biomarker:  Platform Study of Neoadjuvant and Adjuvant Immunotherapy for Patients With Resectable Adenocarcinoma of the Pancreas (clinicaltrials.gov) -  Apr 4, 2023   
    P2,  N=76, Recruiting, 
    Additional immune correlative data will be available and reported at the time of the conference, guiding future applications of novel vaccine approaches. Trial completion date: Jun 2024 --> Dec 2025 | Trial primary completion date: Jun 2023 --> Dec 2024
  • ||||||||||  GVAX Pancreas (allogeneic GM-CSF-secreting tumor cells) / Novartis, Opdivo (nivolumab) / Ono Pharma, BMS
    Trial completion date, Trial primary completion date, Combination therapy:  GVAX Pancreas Vaccine (With CY) in Combination With Nivolumab and SBRT for Patients With Borderline Resectable Pancreatic Cancer (clinicaltrials.gov) -  Mar 10, 2023   
    P2,  N=30, Active, not recruiting, 
    These data provide new evidence that PDACs can become T cell rich and respond to combination immunotherapies. Trial completion date: Jan 2023 --> Jun 2023 | Trial primary completion date: Jan 2023 --> Jun 2023
  • ||||||||||  GVAX Pancreas (allogeneic GM-CSF-secreting tumor cells) / Chinook Therap
    Enrollment closed, Trial completion date, Trial primary completion date, Tumor cell:  A Trial of Boost Vaccinations of Pancreatic Tumor Cell Vaccine (clinicaltrials.gov) -  Mar 8, 2023   
    P2,  N=71, Active, not recruiting, 
    Completed --> Active, not recruiting | Trial completion date: Oct 2022 --> Aug 2023 Recruiting --> Active, not recruiting | Trial completion date: Apr 2023 --> Aug 2023 | Trial primary completion date: Apr 2023 --> Aug 2023
  • ||||||||||  GVAX Pancreas (allogeneic GM-CSF-secreting tumor cells) / Novartis, Keytruda (pembrolizumab) / Merck (MSD)
    Trial completion, Trial completion date, Combination therapy, Metastases:  Study With CY, Pembrolizumab, GVAX Pancreas Vaccine, and SBRT in Patients With Locally Advanced Pancreatic Cancer (clinicaltrials.gov) -  Feb 28, 2023   
    P2,  N=58, Completed, 
    Recruiting --> Active, not recruiting | Trial completion date: Apr 2023 --> Aug 2023 | Trial primary completion date: Apr 2023 --> Aug 2023 Active, not recruiting --> Completed | Trial completion date: Jan 2023 --> Jun 2022
  • ||||||||||  GVAX Pancreas (allogeneic GM-CSF-secreting tumor cells) / Novartis
    Trial completion, Tumor cell:  Adjuvant GVAX Vaccine Therapy in Patients With Pancreatic Cancer (clinicaltrials.gov) -  Jan 25, 2023   
    P2,  N=56, Completed, 
    Trial completion date: Mar 2023 --> Dec 2023 | Trial primary completion date: Mar 2023 --> Dec 2023 Active, not recruiting --> Completed
  • ||||||||||  GVAX Pancreas (allogeneic GM-CSF-secreting tumor cells) / Chinook Therap
    Biomarker, Journal, Tumor microenvironment, PD(L)-1 Biomarker, IO biomarker:  Multi-omic analyses of changes in the tumor microenvironment of pancreatic adenocarcinoma following neoadjuvant treatment with anti-PD-1 therapy. (Pubmed Central) -  Nov 19, 2022   
    Bulk and single-cell RNA sequencing found that nivolumab alters CD4 T cell chemotaxis signaling in association with CD11b neutrophil degranulation, and CD8 T cell expression of CD137 was required for optimal T cell activation. These findings provide insights into PD-1-regulated immune pathways in PDAC that should inform more effective therapeutic combinations that include TAN regulators and T cell activators.
  • ||||||||||  GVAX Pancreas (allogeneic GM-CSF-secreting tumor cells) / Novartis
    Trial primary completion date, Tumor cell:  Adjuvant GVAX Vaccine Therapy in Patients With Pancreatic Cancer (clinicaltrials.gov) -  Jun 22, 2022   
    P2,  N=56, Active, not recruiting, 
    These findings provide insights into PD-1-regulated immune pathways in PDAC that should inform more effective therapeutic combinations that include TAN regulators and T cell activators. Trial primary completion date: Dec 2022 --> Oct 2021
  • ||||||||||  GVAX Pancreas (allogeneic GM-CSF-secreting tumor cells) / Novartis, Keytruda (pembrolizumab) / Merck (MSD)
    Trial completion date, Trial primary completion date, Combination therapy, Metastases:  Study With CY, Pembrolizumab, GVAX Pancreas Vaccine, and SBRT in Patients With Locally Advanced Pancreatic Cancer (clinicaltrials.gov) -  Mar 4, 2022   
    P2,  N=58, Active, not recruiting, 
    Trial completion date: Oct 2023 --> Jul 2023 | Trial primary completion date: Oct 2023 --> Jul 2023 Trial completion date: Jan 2022 --> Jan 2023 | Trial primary completion date: Jan 2022 --> Jan 2023
  • ||||||||||  GVAX Pancreas (allogeneic GM-CSF-secreting tumor cells) / Novartis
    Trial completion date, Trial primary completion date, Tumor cell:  Adjuvant GVAX Vaccine Therapy in Patients With Pancreatic Cancer (clinicaltrials.gov) -  Jan 31, 2022   
    P2,  N=56, Active, not recruiting, 
    In-depth analysis of TLAs is warranted in future neoadjuvant immunotherapy clinical trials. Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: Dec 2021 --> Dec 2022
  • ||||||||||  LY3022855 / Eli Lilly, GVAX Pancreas (allogeneic GM-CSF-secreting tumor cells) / Novartis, Keytruda (pembrolizumab) / Merck (MSD)
    Trial completion date, Trial primary completion date, Combination therapy:  Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas (clinicaltrials.gov) -  Jan 31, 2022   
    P1,  N=12, Active, not recruiting, 
    Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: Dec 2021 --> Dec 2022 Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: Dec 2021 --> Dec 2022
  • ||||||||||  BMS-813160 / BMS, GVAX Pancreas (allogeneic GM-CSF-secreting tumor cells) / Novartis, Opdivo (nivolumab) / Ono Pharma, BMS
    Trial completion date, Trial primary completion date, Metastases:  Trial of Neoadjuvant and Adjuvant Nivolumab and BMS-813160 With or Without GVAX for Locally Advanced Pancreatic Ductal Adenocarcinomas. (clinicaltrials.gov) -  Jan 31, 2022   
    P1/2,  N=30, Recruiting, 
    Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: Dec 2021 --> Dec 2022 Trial completion date: Mar 2022 --> Mar 2023 | Trial primary completion date: Mar 2022 --> Mar 2023
  • ||||||||||  GVAX Pancreas (allogeneic GM-CSF-secreting tumor cells) / Chinook Therap, Opdivo (nivolumab) / Ono Pharma, BMS
    Neoadjuvant and adjuvant antitumor vaccination alone or combination with PD1 blockade and CD137 agonism in patients with resectable pancreatic adenocarcinoma. (In-Person Only | Level 1, West Hall; Online Only) -  Jan 8, 2022 - Abstract #ASCOGI2022ASCO_GI_817;    
    P2
    Treatment was given as follows: Day 1 - Cyclophosphamide 200mg/m2 IV (All Arms), Nivolumab 480mg IV (Arms B, C), Urelumab 8mg IV (Arm C); Day 2 – GVAX ID (All Arms)...SOC regimes included (m)FOLFIRINOX, Gem +/- Cap/NAB-Paclitaxel... Despite a small sample size, combining GVAX with dual immune-targeting of PD-1 blockade and CD137 agonism was safe and may enhance DFS in rPDA pts treated in the perioperative and post-adjuvant settings.
  • ||||||||||  GVAX Pancreas (allogeneic GM-CSF-secreting tumor cells) / Chinook Therap
    Journal:  Trials and tribulations of pancreatic cancer immunotherapy. (Pubmed Central) -  Sep 16, 2021   
    Further, many have shown high rates of serious adverse effects and dose-limiting toxicities, and to date, immunotherapy regimens have not been successfully implemented in PDAC. Here, we provide a comprehensive summary of the key clinical trials exploring immunotherapy in PDAC, followed by a brief discussion of emerging molecular mechanisms that may explain the relative failure of immunotherapy in pancreas cancer thus far.
  • ||||||||||  GVAX Pancreas (allogeneic GM-CSF-secreting tumor cells) / Novartis, Opdivo (nivolumab) / Ono Pharma, BMS
    Enrollment closed, Combination therapy:  GVAX Pancreas Vaccine (With CY) in Combination With Nivolumab and SBRT for Patients With Borderline Resectable Pancreatic Cancer (clinicaltrials.gov) -  Sep 5, 2021   
    P2,  N=30, Active, not recruiting, 
    Here, we provide a comprehensive summary of the key clinical trials exploring immunotherapy in PDAC, followed by a brief discussion of emerging molecular mechanisms that may explain the relative failure of immunotherapy in pancreas cancer thus far. Recruiting --> Active, not recruiting
  • ||||||||||  LY3022855 / Eli Lilly, GVAX Pancreas (allogeneic GM-CSF-secreting tumor cells) / Novartis, Keytruda (pembrolizumab) / Merck (MSD)
    Trial completion date, Trial primary completion date, Combination therapy:  Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas (clinicaltrials.gov) -  Aug 19, 2021   
    P1,  N=12, Active, not recruiting, 
    Trial completion date: Aug 2021 --> Dec 2021 | Trial primary completion date: Aug 2021 --> Dec 2021 Trial completion date: Sep 2021 --> Dec 2021 | Trial primary completion date: Sep 2021 --> Dec 2021